General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo‐Controlled Trials

OBJECTIVE: This pooled analysis of 3 randomized, placebo‐controlled trials (16–24 week treatment and 8–24 week follow‐up) assessed safety of subcutaneous tanezumab (2.5–10 mg every 8 weeks) in 1,840 patients with hip or knee osteoarthritis. METHODS: Overall treatment‐emergent adverse events (TEAEs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Berenbaum, Francis, Schnitzer, Thomas J., Kivitz, Alan J., Viktrup, Lars, Hickman, Anne, Pixton, Glenn, Brown, Mark T., Davignon, Isabelle, West, Christine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Osteoarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310640/
https://www.ncbi.nlm.nih.gov/pubmed/33973384
http://dx.doi.org/10.1002/acr.24637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310640/
https://www.ncbi.nlm.nih.gov/pubmed/33973384
http://dx.doi.org/10.1002/acr.24637

Ejemplares similares